Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.


Creative Commons License

Ulas A., Kos T., Avci N., Cubukcu E., Olmez O. F., Bulut N., ...More

Asian Pacific journal of cancer prevention : APJCP, vol.16, pp.1643-9, 2015 (SCI-Expanded) identifier identifier